帕博利珠单抗作为恶性胸膜间皮瘤的姑息性免疫治疗
该研究汇总澳大利亚和瑞士的注册数据,纳入93例接受帕博利珠单抗治疗的恶性胸膜间皮瘤患者,评估疗效与临床病理特征及PD-L1表达的关系。结果显示总体客观缓解率18%,中位无进展生存期3.1个月,中位总生存期7.2个月;高PD-L1表达和非上皮样亚型与更好的缓解率和无进展生存期相关。
要点
- 帕博利珠单抗二线治疗MPM的总体ORR为18%,mPFS 3.1个月,mOS 7.2个月。
- 高PD-L1表达(≥50%)者ORR 44%,mPFS 6.2个月,优于中/低表达。
- 非上皮样亚型者mPFS 5.6个月,优于上皮样亚型的2.8个月。
核心结论
- 真实世界数据显示帕博利珠单抗治疗MPM的缓解率与早期试验相似但生存期更差。
- 高PD-L1表达和非上皮样组织学亚型与更强的抗肿瘤活性相关。
- 抗PD-L1免疫治疗是MPM患者合理的二线治疗选择。
研究设计与样本
- 研究为澳大利亚和瑞士注册数据的汇总分析。
- 共纳入93例接受帕博利珠单抗治疗的MPM患者,其中瑞士48例、澳大利亚45例。
- PD-L1表达分为阴性(<5%)、中间(5%-49%)和高(≥50%)。
主要发现
- 全队列ORR为18%,mPFS为3.1个月,mOS为7.2个月。
- ECOG PS 0-1且仅接受过一种既往系统治疗的患者(n=35)ORR为37%,mPFS为3.7个月,mOS为10.2个月。
- 非上皮样亚型相比上皮样亚型ORR为24% vs 16%(p=0.54),mPFS为5.6 vs 2.8个月(p=0.02)。
- 高、中间、阴性PD-L1表达的ORR分别为44%、42%、11%(p=0.01),mPFS分别为6.2、3.9、2.7个月(p=0.04)。
- 毒性反应与预期一致。
关键数值与推荐
- PD-L1表达阴性定义为<5%,中间为5%-49%,高为≥50%。
- ECOG PS 0或1且仅一线既往治疗者亚组分析显示ORR 37%、mPFS 3.7个月、mOS 10.2个月。
临床怎么用
- 帕博利珠单抗可作为MPM患者的二线治疗选择。
- 治疗前可考虑检测PD-L1表达,高表达者可能获益更多。
- 非上皮样亚型患者可能从帕博利珠单抗治疗中获益更明显。
局限性
- 研究为回顾性注册数据分析,存在选择偏倚。
- PD-L1表达结果仅66例(71%)可获取。
- 样本量较小(93例),亚组分析效力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There is no approved second-line treatment for malignant pleural mesothelioma (MPM). On the basis of promising early results, pembrolizumab was used off-label in Switzerland and Australia. We investigated outcomes in association with clinicopathological features and expression of programmed death ligand 1 (PD-L1). METHODS: Registry data in Australia and Switzerland were pooled. Patient characteristics, including age, sex, histological subtype, and previous treatments were captured. Outcomes were assessed locally. PD-L1 expression was categorized as negative (<5%), intermediate (5%-49%), and high (≥50%). RESULTS: A total of 93 patients (48 from Switzerland and 45 from Australia) were treated; 68 patients (73%) had epithelioid MPM, and 67 (72%) had an Eastern Cooperative Oncology Group performance status of 0 or 1. Pembrolizumab was the second-line treatment in 48 of 93 patients (52%). PD-L1 expression results were available for 66 patients (71%). Most (68%) were negative, 18% were intermediate, and 14% were high for PD-L1 expression. In the full cohort, the overall response rate (ORR) was 18%, the median progression-free survival (mPFS) was 3.1 months, and the median overall survival was 7.2 months. In patients with an Eastern Cooperative Oncology Group performance status of 0 or 1 and only one previous systemic treatment (n = 35), the ORR was 37%, the mPFS was 3.7 months, and the median overall survival was 10.2 months. The nonepitheloid histological subtype showed an improved ORR (24% versus 16% [p = 0.54) and mPFS (5.6 versus 2.8 months [p = 0.02]). Compared with intermediate and negative PD-L1 expression, high PD-L1 expression was associated with an improved ORR (44% versus 42% versus 11% [p = 0.01]) and mPFS (6.2 versus 3.9 versus 2.7 months [p = 0.04]). Toxicity was as expected. CONCLUSION: These real-world data demonstrate similar response rates but inferior survival compared with those in early-phase trials. High PD-L1 expression and nonepitheloid histological subtype were associated with greater activity. Anti-PD-L1 immunotherapy is a reasonable second-line therapy in patients with MPM.
引用
- Metaxas Y, Rivalland G, Mauti LA, et al. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. J Thorac Oncol. 2018. PMID: 30142389. doi:10.1016/j.jtho.2018.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。